Aortic Stenosis

Aortic stenosis (AS) is a progressive valvular heart disease characterized by a narrowing of the aortic valve opening, which obstructs blood flow from the left ventricle to the aorta during systole. This obstruction leads to increased pressure within the left ventricle, causing compensatory left ventricular hypertrophy (LVH). Over time, LVH can lead to myocardial dysfunction, heart failure, and potentially sudden cardiac death if left untreated.

The primary causes of aortic stenosis include:

1. Calcific Degenerative AS: Most common cause in older adults, resulting from age-related calcification and fibrosis of a previously normal trileaflet aortic valve.


2. Congenital Bicuspid Aortic Valve: Affects 1-2% of the population, where the aortic valve has two leaflets instead of the normal three. This abnormality often leads to premature calcification and stenosis, typically manifesting in younger adults or middle age.


3. Rheumatic Heart Disease: A sequela of rheumatic fever, causing inflammation and scarring of the valve leaflets, leading to commissural fusion, fibrosis, and calcification.

The narrowed aortic valve orifice increases the resistance to left ventricular outflow. To maintain adequate cardiac output, the left ventricle must generate higher pressures, leading to increased wall stress. This sustained pressure overload triggers compensatory concentric left ventricular hypertrophy (LVH), which initially helps normalize wall stress and preserve systolic function. However, LVH also increases myocardial oxygen demand and can impair diastolic function due to reduced ventricular compliance. As the disease progresses, the LVH becomes maladaptive, leading to myocardial fibrosis, systolic dysfunction, pulmonary hypertension, and eventually, congestive heart failure. Reduced cardiac output can also lead to symptoms such as angina (due to increased myocardial oxygen demand and reduced coronary flow reserve) and syncope (due to transient cerebral hypoperfusion).

Aortic stenosis is the most common primary valvular heart disease in developed countries. Its prevalence increases significantly with age:

• Affects approximately 2-7% of individuals over 65 years.


• Severe AS affects about 3% of those over 75 years.


• Congenital bicuspid aortic valve is more prevalent in males and is a common cause of AS in individuals under

• Rheumatic AS is more common in developing countries.

• Advanced age
• Congenital bicuspid aortic valve
• Hyperlipidemia
• Hypertension
• Diabetes mellitus
• Smoking
• Chronic kidney disease
• Male gender (for bicuspid valve AS)
• History of rheumatic fever

A. Early Symptoms

• Often asymptomatic for many years


• Mild fatigue or decreased exercise tolerance B. Common Symptoms (Classic Triad)


• Angina pectoris (chest pain)


• Syncope (fainting or lightheadedness)


• Dyspnea (shortness of breath), especially on exertion C. Advanced Symptoms


• Orthopnea and paroxysmal nocturnal dyspnea


• Peripheral edema


• Signs of heart failure (e.g., severe fatigue, weakness, weight gain)


• Palpitations D. Emergency Symptoms


• Sudden collapse or profound syncope


• Acute pulmonary edema


• Sudden cardiac arrest

• Vital Signs: Narrow pulse pressure (in severe AS), normal or slightly elevated blood pressure.
• Inspection: Jugular venous distension (if heart failure present).
• Palpation: Apex beat may be sustained and displaced laterally (LVH), thrill over the right second intercostal space. Pulsus parvus et tardus (weak and delayed carotid upstroke).

• Diminished or absent A2 heart sound (closure of aortic valve).
• S4 heart sound: Suggests stiff, hypertrophied ventricle.
• Ejection click: May be present in congenital bicuspid valve.

A. Clinical Assessment
Detailed history of symptoms (angina, syncope, dyspnea), physical examination findings.
B. Laboratory Testing
Baseline blood tests, BNP/NT-proBNP.
C. Imaging Studies
Echocardiography (Transthoracic and Transesophageal), Cardiac CT/MRI, Chest X-ray.
D. Functional Tests
Exercise stress test (only in asymptomatic patients with normal exercise tolerance).
E. Biopsy Findings
Not typically used for diagnosis.
F. Genetic Testing
Considered for familial bicuspid aortic valve or specific genetic syndromes.
G. Differential Diagnosis
Hypertrophic cardiomyopathy, mitral regurgitation, pulmonary stenosis.

Complete Blood Count (CBC)
Type: Blood Test
Purpose: Assess for anemia or infection as contributing factors or complications.
Expected Findings: Generally normal, unless comorbid conditions exist.
Interpretation: Anemia can exacerbate symptoms. Electrolytes and Renal Function (BUN, Creatinine)
Type: Blood Test
Purpose: Baseline assessment, identify electrolyte imbalances or renal impairment that may affect treatment choices.
Expected Findings: May show renal insufficiency in advanced disease or comorbidities.
Interpretation: Renal dysfunction is a known risk factor and can impact medication metabolism. Lipid Panel
Type: Blood Test
Purpose: Assess for hyperlipidemia as a risk factor for calcific AS.
Expected Findings: May show elevated LDL cholesterol.
Interpretation: Hyperlipidemia management is crucial for risk factor modification. B-type Natriuretic Peptide (BNP) / N-terminal pro-BNP (NT-proBNP)
Type: Blood Test
Purpose: Biomarker for myocardial stretch and heart failure; can help assess symptom severity and prognosis.
Expected Findings: Elevated levels in symptomatic AS or with LV dysfunction.
Interpretation: Higher levels correlate with worse prognosis and increased likelihood of heart failure.

Echocardiography (Transthoracic Echocardiogram - TTE)
Purpose: Gold standard for diagnosis and severity assessment. Visualizes valve morphology (bicuspid vs. trileaflet), leaflet mobility, measures aortic valve area (AVA), peak and mean pressure gradients, and left ventricular size and function.
Typical Findings: Thickened, calcified, and/or restricted valve leaflets; reduced AVA (<1.0 cm² for severe AS); high transvalvular velocity (>4.0 m/s) and mean gradient (>40 mmHg); LVH; potentially reduced LV ejection fraction.
Clinical Importance: Crucial for confirming AS, quantifying its severity, monitoring progression, and guiding treatment decisions. Transesophageal Echocardiography (TEE)
Purpose: Provides more detailed views of the aortic valve and surrounding structures, especially useful when TTE is suboptimal or for evaluating the aorta prior to intervention.
Typical Findings: High-resolution imaging of valve leaflets, identification of vegetation in suspected endocarditis, assessment of aortic root dimensions.
Clinical Importance: Used for further detailed assessment, particularly when considering surgical or transcatheter interventions, and for ruling out infective endocarditis. Cardiac Computed Tomography (CT)
Purpose: Quantifies aortic valve calcification (calcium score), assesses aortic annulus dimensions for TAVI planning, evaluates ascending aorta for concomitant aneurysms.
Typical Findings: High calcium score (e.g., >1300 AU for women, >2000 AU for men, indicating severe AS); detailed anatomical measurements of the aortic root and peripheral vasculature.
Clinical Importance: Essential for TAVI planning, risk stratification, and detecting associated aortic disease. Cardiac Magnetic Resonance Imaging (MRI)
Purpose: Provides comprehensive assessment of cardiac structure and function, including LV volumes, mass, and fibrosis (late gadolinium enhancement). Can be used to quantify aortic flow and valve area if echocardiography is non-diagnostic.
Typical Findings: Detailed LV mass and volume, presence of myocardial fibrosis, sometimes used to confirm AS severity and exclude hypertrophic cardiomyopathy.
Clinical Importance: Useful for evaluating myocardial consequences of AS, particularly when echocardiographic windows are poor, or for differentiation from other conditions. Chest X-ray
Purpose: Assess for cardiomegaly, pulmonary congestion, and calcification of the aortic valve or root.
Typical Findings: Enlarged cardiac silhouette (cardiomegaly), pulmonary venous congestion, calcification in the region of the aortic valve (lateral view).
Clinical Importance: Provides supportive evidence, helps assess for heart failure, and screens for other pulmonary conditions.

• Hypertrophic Cardiomyopathy (HCM): Similar symptoms (dyspnea, angina, syncope) and murmur. Distinguished by characteristic septal hypertrophy on echocardiography, no aortic valve calcification, and dynamic outflow tract obstruction that changes with maneuvers.
• Mitral Regurgitation: May have a systolic murmur, but typically heard best at the apex and radiating to the axilla. Echocardiography clarifies valve pathology.
• Subaortic Stenosis: Obstruction occurs below the aortic valve. Echocardiography reveals a subvalvular membrane or fibromuscular ridge.
• Pulmonary Stenosis: Murmur is typically heard at the left upper sternal border and does not radiate to the carotids. Symptoms of right heart failure may be present.

• Heart failure (systolic and/or diastolic)
• Sudden cardiac death (especially in symptomatic patients)
• Ventricular arrhythmias
• Atrial fibrillation
• Infective endocarditis (on the diseased native valve or prosthetic valve)
• Bleeding or stroke (associated with prosthetic valves, especially mechanical, or during interventional procedures)
• Aortic dissection (in patients with bicuspid aortic valve and dilated aorta)
• Renal dysfunction

A. Lifestyle Modifications

• Smoking cessation


• Healthy diet (low cholesterol, low sodium)


• Regular, moderate exercise (as tolerated and advised by physician for asymptomatic patients)


• Management of comorbidities (hypertension, hyperlipidemia, diabetes) B. Preventive Measures


• Primary prevention: Aggressive management of cardiovascular risk factors to slow progression of degenerative AS.


• Secondary prevention: Regular follow-up with echocardiography for asymptomatic AS patients to monitor disease progression. C. Medical Treatment


• There is no specific medical treatment to halt or reverse the progression of aortic stenosis itself.


• Diuretics: For management of heart failure symptoms (e.g., furosemide)


• Beta-blockers/Calcium channel blockers: Use with caution, especially in symptomatic AS, due to potential for exacerbating outflow obstruction or causing hypotension. May be used for rate control in atrial fibrillation if carefully monitored.


• ACE inhibitors/ARBs: Used cautiously in symptomatic AS to avoid hypotension, but may be beneficial in asymptomatic patients with hypertension.


• Statins: While they do not directly reduce valve calcification or progression of AS, they are important for managing hyperlipidemia and overall cardiovascular risk. D. Surgical Treatment


• Surgical Aortic Valve Replacement (SAVR): Open-heart surgery to replace the diseased aortic valve with a prosthetic mechanical or bioprosthetic valve. Indicated for symptomatic severe AS, asymptomatic severe AS with LV dysfunction, or when undergoing other cardiac surgery. E. Interventional Procedures


• Transcatheter Aortic Valve Implantation (TAVI/TAVR): A minimally invasive procedure where a new valve is delivered via a catheter (usually transfemoral) and deployed within the native aortic valve. Primarily indicated for patients with severe AS who are at intermediate or high surgical risk.


• Balloon Aortic Valvuloplasty (BAV): A temporary measure to improve valve opening using a balloon. Primarily used as a bridge to definitive treatment or in patients who are not candidates for SAVR/TAVI due to high risk. F. Rehabilitation


• Cardiac Rehabilitation: Structured exercise and education program post-surgery or TAVI to improve physical function, reduce cardiovascular risk factors, and enhance quality of life. G. Emergency Management


• For acute pulmonary edema or heart failure: Diuretics (e.g., intravenous furosemide), oxygen, judicious use of vasodilators (with extreme caution due to fixed outflow obstruction).


• For syncope/collapse: Stabilization, assessment for arrhythmias, and urgent evaluation for definitive valve replacement.

The prognosis for asymptomatic severe aortic stenosis is generally good, but once symptoms develop (angina, syncope, dyspnea), the prognosis without intervention is poor, with a 2-year survival rate often less than 50%. With successful aortic valve replacement (SAVR or TAVI), the prognosis dramatically improves, with symptom resolution and normalization of life expectancy, although long-term outcomes depend on LV function and comorbidities.

• Primary Prevention: Management of traditional cardiovascular risk factors (hypertension, hyperlipidemia, diabetes, smoking) may slow the progression of degenerative calcific AS, although definitive evidence for this is ongoing. Regular exercise and a heart-healthy diet.
• Secondary Prevention: Regular echocardiographic screening for individuals at high risk (e.g., those with a known bicuspid aortic valve, strong family history, or murmurs suggestive of AS) to monitor disease progression and determine optimal timing for intervention.

The following homeopathic remedies have been historically indicated for symptoms associated with Aortic Stenosis. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Aortic Stenosis.